Do you foresee any potential issue with switching to/from Eliquis/Xarelto from/to Pradaxa that needs careful bridging?
The pharmacodynamic features of Warfarin (very long: onset of action, elimination half-life, duration of action, time to steady-state concentration) are the cause for the switching problems. All three new anticoagulants have more similar and shorter time to steady-state concentrations and other parameters. Although I didn't see protocols for management of transitions from one to another (just to LMWH and/or Warfarin), I think it will be prety straightforward.
Market Data 
Markets 
AI
